For fenebrutinib, a Ph II study comparing fenebrutinib and adalimumab, a TNF-alpha inhibitor, in patients with rheumatoid arthritis had commonly reported non-serious adverse events of nausea, headache, anemia and upper respiratory tract infections (74). Here, TNF is linked to anemia.